Study finds differences in bleeding risk among common blood thinners

Credit: Unsplash+

When patients are diagnosed with conditions like blood clots or atrial fibrillation, doctors often prescribe blood thinners to prevent future clotting.

A recent study compared three commonly prescribed blood thinners: rivaroxaban (Xarelto), apixaban (Eliquis), and warfarin. The study focused on their association with bleeding complications in patients with these conditions.

The study examined data collected over ten years from the Michigan Anticoagulation Quality Improvement Initiative registry, a multi-center initiative sponsored by Blue Cross Blue Shield of Michigan. This data included information about patients prescribed these blood thinners.

Key Findings

The study revealed that rivaroxaban was linked to a significantly higher risk of bleeding complications compared to apixaban and warfarin in patients with blood clots or atrial fibrillation.

Over one year, if 100 patients took rivaroxaban, there were nearly 40 bleeding events, while warfarin resulted in around 25 such events. Apixaban and warfarin had similar bleeding rates, but warfarin had more major bleeds.

Apixaban showed a higher rate of blood clots compared to warfarin, but this appeared to be influenced by other thrombotic events, including heart attacks.

Apixaban had a lower mortality rate compared to rivaroxaban and warfarin.

The study’s findings provide insights into the bleeding risks associated with commonly prescribed anticoagulants. Although these findings are valuable, further research through randomized clinical trials is necessary to confirm them.

These results can help healthcare providers make more informed decisions when choosing anticoagulants for their patients.

This study compared the bleeding risk associated with three commonly prescribed blood thinners: rivaroxaban, apixaban, and warfarin. Rivaroxaban showed a higher risk of bleeding complications compared to the other two.

While the findings provide valuable insights, additional research is needed to confirm these results through randomized trials. These findings will assist healthcare providers in selecting the most appropriate anticoagulant treatment for their patients.

If you care about heart disease, please read studies about a big cause of heart failure, and common blood test could advance heart failure treatment.

For more information about heart health, please see recent studies about a new way to repair human heart, and results showing drinking coffee may help reduce heart failure risk.

Copyright © 2023 Knowridge Science Report. All rights reserved.